Tyra Biosciences, Inc. TYRA

TYRA Company Overview

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines designed to overcome tumor resistance mechanisms in cancer. The company operates within the oncology and biopharmaceutical industries, with a core emphasis on targeted therapies against fibroblast growth factor receptor (FGFR) alterations. Tyra Biosciences’ approach centers on its proprietary drug design platform, which aims to predict and counteract acquired resistance mutations that limit the durability of existing targeted cancer therapies.

The company’s primary value drivers are its internally developed small-molecule kinase inhibitors, particularly TYRA-300 and TYRA-200, which are being evaluated for cancers driven by FGFR gene alterations. Tyra Biosciences primarily serves oncology patients with genetically defined tumors, positioning itself within the precision oncology segment. Founded in 2018, the company has evolved from a discovery-stage enterprise into a publicly traded clinical-stage organization following its initial public offering in 2021, with a strategic focus on advancing differentiated FGFR inhibitors into clinical development.